- Home
- EVOK vs OGEN Comparison
EVOK vs OGEN Comparison
Compare EVOK & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- OGEN
- Stock Information
- Founded
- EVOK 2007
- OGEN 1996
- Country
- EVOK United States
- OGEN United States
- Employees
- EVOK N/A
- OGEN N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- OGEN Health Care
- Exchange
- EVOK Nasdaq
- OGEN Nasdaq
- Market Cap
- EVOK 4.3M
- OGEN 4.5M
- IPO Year
- EVOK 2013
- OGEN N/A
- Fundamental
- Price
- EVOK $4.45
- OGEN $0.27
- Analyst Decision
- EVOK
- OGEN
- Analyst Count
- EVOK 0
- OGEN 0
- Target Price
- EVOK N/A
- OGEN N/A
- AVG Volume (30 Days)
- EVOK 1.2M
- OGEN 633.0K
- Earning Date
- EVOK 11-07-2024
- OGEN 11-13-2024
- Dividend Yield
- EVOK N/A
- OGEN N/A
- EPS Growth
- EVOK N/A
- OGEN N/A
- EPS
- EVOK N/A
- OGEN N/A
- Revenue
- EVOK $8,617,036.00
- OGEN N/A
- Revenue This Year
- EVOK $124.10
- OGEN N/A
- Revenue Next Year
- EVOK $75.70
- OGEN N/A
- P/E Ratio
- EVOK N/A
- OGEN N/A
- Revenue Growth
- EVOK 100.35
- OGEN N/A
- 52 Week Low
- EVOK $3.54
- OGEN $0.25
- 52 Week High
- EVOK $17.40
- OGEN $7.74
- Technical
- Relative Strength Index (RSI)
- EVOK 40.54
- OGEN 35.91
- Support Level
- EVOK $4.28
- OGEN $0.25
- Resistance Level
- EVOK $4.79
- OGEN $0.43
- Average True Range (ATR)
- EVOK 0.45
- OGEN 0.03
- MACD
- EVOK -0.13
- OGEN -0.00
- Stochastic Oscillator
- EVOK 22.82
- OGEN 12.11
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.